Tuesday, July 16, 2024 at 2-3pm ET                             Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Ulcerative colitis is a chronic, progressive, inflammatory bowel disease that damages the bowel over time and may result in decreased quality of life, hospitalizations, surgeries, and disability. The STRIDE II Recommendations for moderate to severe ulcerative colitis include long-term goals for the management of the disease.

There is a need for new treatment options, with a focus on long-term patient outcomes. An IL-23 inhibitor was recently approved for the treatment of moderate to severe ulcerative colitis. The objective of this webinar is to review the ulcerative colitis disease state, treatment guidelines, and the pivotal trials program for this recently approved indication for an IL-23 inhibitor.

Learning Objectives

• Discuss the epidemiology of ulcerative colitis and clinical burden of the disease that often requires multiple treatment options for patients.
• Review the Treat to Target approach from the STRIDE-II guidelines discussing the impact of disease progression and long-term outcomes with the early appropriate use of advanced treatment options for moderate to severe ulcerative colitis.
• Review and discuss the efficacy and safety data of an IL-23 inhibitor in patients with moderate to severe ulcerative colitis from its pivotal trials program.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.